Surrey, UK, 23rd September 2011 – NextPharma, the leading European provider of
product development, contract manufacturing and cold chain and logistics outsourcing
services to the pharmaceutical and biotech industry, today announced that Bill
Wedlake, NextPharma?s Chief Executive Officer will step down effective 30th
September, 2011. Franck Latrille, NextPharma?s new CEO, replaces Bill and will take
up his position on Monday 3rd October, 2011.
Bill Wedlake joined NextPharma in July 2000 as Chief Financial Officer in the same
year that it was founded. In 2003 he was appointed Chief Executive Officer and
joined the Board of Directors. Bill who has contributed significantly to the growth and
development of the NextPharma business is working closely with Franck to ensure a
smooth transition process. The rest of the NextPharma executive management team
David Finnigan of Sun European Partners, NextPharma?s shareholder commented “I
am very grateful to Bill for his considerable contributions to NextPharma over the
past eleven years and I wish him every success for the future”. Finnigan continued
“NextPharma is in a tremendous position to extend its share of the outsourcing market
and its Board of Directors is pleased to be able to appoint an executive with Frank?s
experience and track record to lead NextPharma to its next stage of growth and
Franck Latrille joins NextPharma with a broad and deep experience of the global
pharmaceutical industry, having most recently held executive board positions at
Merck-Serono SA, including Deputy CEO and EVP Marketing and Sales. Previously
at Serono SA he held executive board positions with responsibility for pharmaceutical
manufacturing and product development operations. He holds a PhD in biochemistry
NextPharma develops, manufactures, packages, and distributes a broad range of
products and formulations for its customers from tablets and capsules to antibiotics,
hormones, steriles and controlled release medicines. It has an established leadership
position in the high technology area of injectables manufacturing, with particular
expertise in product development and manufacture of oncology medicines.
NextPharma has recently been acquired by Sun European Partners with a view to
leveraging NextPharma?s strong track record, reputation and state of the art facilities,
to grow the business both organically and by acquisition.
NextPharma Technologies Holding Limited
Tel +44 (0) 1483 479 120
NextPharma Technologies, headquartered in the UK and founded in 2000, is a world
class outsourcing partner to the pharmaceutical and biotechnology industry.
NextPharma offers a full range of services from early phase product development,
through clinical trial packaging (Phases I through III) to high volume commercial
manufacturing for New Chemical Entities (NCEs)/New Biological Entities (NBEs)
and generic products. The company is a world leader in lyophilization, sterile fill
finish and pellet technologies and in specialist product manufacturing including
cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Its sterile
development and production offers a full range of drug delivery technologies
including pre-filled syringes, vials and ampoules. Additionally NextPharma has
significant expertise in paediatric drug formulation, development and manufacture.
NextPharma offers „one-stop? logistics solutions tailored to meet the needs of the
global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.
NextPharma operates globally with seven product development centers, seven
manufacturing plants and six temperature controlled storage and distribution sites
across Europe and North America, supplying customers in North America, Europe
NextPharma has 1,200 employees dedicated to serving over 200 customers worldwide
and a customer base, which includes many of the world?s leading pharmaceutical,
specialty pharma and biotech companies.
NextPharma has a proven track record in almost all pharmaceutical technologies and 3
product forms and in addition to the specialist areas above have capabilities in solids,
semi-solids, liquids, sprays and dry dosage form technologies.
All of its sites are either FDA inspected, in the process of upgrade for inspection or
targeted for upgrade for inspection.